ProQR Therapeutics (PRQR) Income from Continuing Operations (2012 - 2026)
ProQR Therapeutics (PRQR) posted Income from Continuing Operations of 15668089.03 for Q1 2026, down 33.8% sequentially from 11710277.76 in Q4 2025, and down 42.54% YoY from 27267033.7 in Q1 2025.
Powered by 
Analysis
ProQR Therapeutics (PRQR) Income from Continuing Operations (2012 - 2026) Analysis & Trends
ProQR Therapeutics has reported Income from Continuing Operations for 14 years, with the latest figure at 15668089.03 in Q1 2026.
- Quarterly Income from Continuing Operations fell 42.54% year-over-year to 15668089.03 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 53990373.62 (down 64.86% YoY) and the FY2025 annual result came in at 50389115.66, down 69.85% from the prior year.
- Income from Continuing Operations retreated to 15668089.03 in Q1 2026 per PRQR's latest filing, from 11710277.76 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 3329736.39 in Q2 2024 and troughed at 23357683.12 in Q3 2022.
- A 5-year average of 11403034.43 and a median of 10992192.39 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations surged 74.74% in 2023, then plunged 312.81% in 2025.
- Over 5 years, Income from Continuing Operations stood at 13765177.45 in 2022, then surged by 46.81% to 7321771.08 in 2023, then plunged by 30.05% to 9522253.61 in 2024, then slipped by 22.98% to 11710277.76 in 2025, then tumbled by 33.8% to 15668089.03 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 15668089.03, 11710277.76, and 12866620.34 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | ProQR Therapeutics | 218.57 Mn | 82.18 Mn | - | -10.09 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.09 Mn |
| Mar 31, 2026 | -15.67 Mn |
| Dec 31, 2025 | -10.43 Mn |
| Sep 30, 2025 | -12.87 Mn |
| Jun 30, 2025 | -13.75 Mn |
| Mar 31, 2025 | -10.60 Mn |
| Dec 31, 2024 | -9.52 Mn |
| Sep 30, 2024 | -8.90 Mn |
| Jun 30, 2024 | -3.33 Mn |
| Mar 31, 2024 | -8.31 Mn |
| Dec 31, 2023 | -5.90 Mn |
| Sep 30, 2023 | -5.90 Mn |
| Jun 30, 2023 | -8.78 Mn |
| Mar 31, 2023 | -9.50 Mn |
| Dec 31, 2022 | -13.77 Mn |
| Sep 30, 2022 | -23.36 Mn |
| Jun 30, 2022 | -14.34 Mn |
| Mar 31, 2022 | -15.83 Mn |
| Dec 31, 2021 | -20.82 Mn |
| Sep 30, 2021 | -17.69 Mn |